This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. 1 week to 6 months [clinicaltrials_resource:8a8fd89a75b3a665f62efeec09338f16]
We will 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment after the initial PET/CT scan (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), we will measure response to treatment.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. 1 week to 6 months [clinicaltrials_resource:8a8fd89a75b3a665f62efeec09338f16]
We will 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment after the initial PET/CT scan (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), we will measure response to treatment.
Bio2RDF identifier
8a8fd89a75b3a665f62efeec09338f16
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8a8fd89a75b3a665f62efeec09338f16
measure [clinicaltrials_vocabulary:measure]
This protocol is designed to t ...... atin receptor positive tumors.
time frame [clinicaltrials_vocabulary:time-frame]
1 week to 6 months
description
We will 1) compare this unique ...... measure response to treatment.
identifier
clinicaltrials_resource:8a8fd89a75b3a665f62efeec09338f16
title
This protocol is designed to t ...... ive tumors. 1 week to 6 months
@en
type
label
This protocol is designed to t ...... fd89a75b3a665f62efeec09338f16]
@en